JAMA Internal Medicine commentary highlights opportunity to discover modifiable risk factor for dementia REGENSTRIEF INSTITUTE INDIANAPOLIS – In a commentary published in JAMA Internal Medicine, three Regenstrief Institute research scientists write that while they and other researchers have identified a strong and consistent link between anticholinergic drugs and cognitive impairment from observational studies, randomized clinical trials represent the only rigorous method to definitively establish...